Sector revisions Sanofi

Equities

Real-time Euronext Paris Other stock markets 16:29:58 14/07/2025 BST			5-day change	1st Jan Change
83.46 ^EUR	+0.52%		+1.24%	-10.97%

07-11	SANOFI : UBS reiterates its Buy rating	ZD
07-10	Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	RE

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility (Composite)	Nbr of analysts
	SANOFI							23
	ELI LILLY AND COMPANY							27
	JOHNSON & JOHNSON							23
	ABBVIE INC.							27
	NOVO NORDISK A/S							22
	ROCHE HOLDING AG							20
	NOVARTIS AG							19
	ASTRAZENECA PLC							20
	MERCK & CO., INC.							24
	AMGEN INC.							28
	PFIZER, INC.							23
	GILEAD SCIENCES, INC.							26
	VERTEX PHARMACEUTICALS INCORPORATED							28
	BRISTOL-MYERS SQUIBB COMPANY							21
	GSK PLC							19
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	JIANGSU HENGRUI MEDICINE CO., LTD.							18
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							16
	HALEON PLC							17
	Average							22
	Weighted average by Cap.							23